| __timestamp | Gilead Sciences, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 7751000 |
| Thursday, January 1, 2015 | 3426000000 | 10251000 |
| Friday, January 1, 2016 | 3398000000 | 9575000 |
| Sunday, January 1, 2017 | 3878000000 | 10912000 |
| Monday, January 1, 2018 | 4056000000 | 11049000 |
| Tuesday, January 1, 2019 | 4381000000 | 11646000 |
| Wednesday, January 1, 2020 | 5151000000 | 13265000 |
| Friday, January 1, 2021 | 5246000000 | 25805000 |
| Saturday, January 1, 2022 | 5673000000 | 35182000 |
| Sunday, January 1, 2023 | 6090000000 | 94999000 |
| Monday, January 1, 2024 | 6091000000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding a company's operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Gilead Sciences, Inc. and Viridian Therapeutics, Inc. over the past decade. Gilead Sciences, a leader in the biotech industry, has seen its SG&A expenses grow by approximately 104% from 2014 to 2023, reflecting its expansive operations and market reach. In contrast, Viridian Therapeutics, a smaller player, experienced a staggering 1,125% increase in the same period, indicating rapid growth and investment in its administrative capabilities. While Gilead's expenses are significantly higher, the relative growth in Viridian's SG&A expenses highlights its aggressive expansion strategy. This comparison not only underscores the scale of operations but also provides insights into the strategic priorities of these companies in a competitive market.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Gilead Sciences, Inc.
Cost Management Insights: SG&A Expenses for Novartis AG and Viridian Therapeutics, Inc.
Amgen Inc. and Gilead Sciences, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.
Gilead Sciences, Inc. or BioMarin Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Gilead Sciences, Inc. or Grifols, S.A.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Viridian Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Soleno Therapeutics, Inc. or Viridian Therapeutics, Inc.